Cell cycle-related kinase: A novel candidate oncogene in human glioblastoma

Samuel S.M. Ng, Yuen Ting Cheung, Xiao Meng An, Yang Chao Chen, Ming Li, Gloria Hoi-Yee, William Cheung, Johnny Sze, Lihui Lai, Ying Peng, Harry H.X. Xia, Benjamin C.Y. Wong, Suet Yi Leung, Dan Xie, Ming Liang He, Hsiang Fu Kung, Marie C. Lin

Research output: Contribution to journalArticlepeer-review

39 Scopus citations

Abstract

Background: Median survival for patients with glioblastoma multiforme, the most aggressive glioma, is only 12-15 months, despite multimodal treatment that includes surgery, chemotherapy, and radiotherapy. Thus, identification of genes that control the progression of glioblastoma multiforme is crucial for devising new therapies. We investigated the involvement of cell cycle-related kinase (CCRK), a novel protein kinase that is homologous to cyclin-dependent kinase 7, in glioblastoma multiforme carcinogenesis. Methods: We analyzed the expression levels of CCRK in 26 glioma patient samples (19 high-grade and seven low-grade) and normal brain by semiquantitative reverse transcription-polymerase chain reaction assays. CCRK expression was knocked down in human glioma U-373 MG and U-87 MG cells with small-interfering RNAs and short hairpin RNAs (siCCRK and shCCRK, respectively), and cell proliferation, cell cycle distribution, and cyclin-dependent kinase 2 (CDK2) phosphorylation were examined. A subcutaneous nude mouse xenograft model (n = 4 mice per group) was used to study the effect of CCRK knockdown and overexpression on tumorigenicity and growth of glioblastoma multiforme cells in vivo. All statistical tests were two-sided. Results: CCRK mRNA was elevated at least 1.5-fold and as much as 3.7-fold in 14 (74%) of 19 high-grade glioblastoma multiforme patient samples and in four (80%) of five glioma cell lines examined compared with normal brain tissue. Suppression of CCRK by siCCRK inhibited the proliferation of U-373 MG and U-87 MG glioblastoma cells in a time- and dose-dependent manner. The growth-inhibiting effect of siCCRK was mediated via G1- to S-phase cell cycle arrest and reduced CDK2 phosphorylation. CCRK knockdown statistically significantly suppressed glioma cell growth in vivo as indicated by the mean tumor volumes at week 6 after tumor cell injection (U-373-control = 1352 mm3, U-373-shCCRK = 294 mm3, difference = 1058 mm3, 95% confidence interval [CI] = 677 to 1439 mm3, P<.001; U-87-control = 1910 mm3, U-87-shCCRK = 552 mm3, difference = 1358 mm3, 95% CI = 977 to 1739 mm3, P<.001). Conclusions: CCRK is a candidate oncogene in glioblastoma multiforme tumorigenesis.

Original languageEnglish (US)
Pages (from-to)936-948
Number of pages13
JournalJournal of the National Cancer Institute
Volume99
Issue number12
DOIs
StatePublished - Jun 20 2007
Externally publishedYes

Bibliographical note

Funding Information:
This work was supported by the Research Grants Council of the Hong Kong Special Administrative Region, China (HKU7243/02M to M. C. Lin), the Committee on Research and Conference Grants of the University of Hong Kong (200507176197 to S. S. M. Ng), Li Ka Shing Institute of Health Sciences (H.-F. Kung), AoE scheme of UGC, Shanghai Metropolitan Fund for Research and Development (04JC14096), and Foundation of Guangzhou Science and Technology Bureau (2005Z1-E0131). The study sponsors had no role in the design of the study; the collection, analysis, or interpretation of the data; the writing of the manuscript; or the decision to submit the manuscript for publication.

Fingerprint

Dive into the research topics of 'Cell cycle-related kinase: A novel candidate oncogene in human glioblastoma'. Together they form a unique fingerprint.

Cite this